EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Prediction of Hepatocellular Carcinoma and Other Liver‐Related Events in Chronic Hepatitis B Patients With Metabolic Dysfunction or Metabolic Dysfunction‐Associated Steatotic Liver Disease

Lesley A Patmore iD, Ivana Carey, Jordan J Feld, Willem P Brouwer iD, Keyur Patel iD, Maria Buti iD, Pieter Honkoop, Douwe F Postma, Hans Blokzijl, Özgur M Koc, Eva van Oorschot, Kosh Agarwal und 11 weitere

Alimentary Pharmacology & Therapeutics · 2026

DOI: 10.1111/apt.70360 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2026. Verfasst von Lesley A Patmore und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Hepatitis B, Chronic, Liver Neoplasms, Fatty Liver. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Stichting voor Lever- en Maag-Darm Onderzoek, Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Metabolic dysfunction and metabolic dysfunction‐associated steatotic liver disease (MASLD) are associated with an increased risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). We aimed to study risk factors for HCC and to assess the performance of the PAGE‐B score in this population.

Methods

We included CHB patients with ≥ 1 metabolic comorbidity from nine centres. Steatosis was diagnosed by ultrasound, CAP, or histology. Risk factors were analysed by Cox regression, and the performance of the PAGE‐B score was assessed in the overall population and across relevant subgroups.

Results

We included 1922 patients. 1730 (90.0%) were overweight, 434 (22.6%) had hypertension, 254 (13.2%) dyslipidemia, 230 (12.0%) diabetes and 732 (38.1%) MASLD. Presence of cirrhosis, older age, lower platelets and lower albumin were independent risk factors for HCC. The 5‐year HCC risk was 0.1%/2.0%/12.4% patients with low/intermediate/high PAGE‐B scores ( p < 0.001). Consistent results were obtained in patients with MASLD (0/2.8/11.1% for low, intermediate and high PAGE‐B scores ( p < 0.001)). PAGE‐B stratified risk in patients without cirrhosis (0% vs. 1.2% and 1.8%, p < 0.001). Among the subset of patients with cirrhosis, risks were 4.2% (low), 6.9% (intermediate) and 27.3% (high) ( p < 0.001).

Conclusions

CHB patients with metabolic dysfunction and/or MASLD are at significant risk of HCC. The PAGE‐B score can be used to stratify HCC risk in this population, with negligible 5‐year HCC incidence in those without cirrhosis and low PAGE‐B scores. However, caution should be exercised in patients with cirrhosis in whom HCC risk remains significant even among those with a low PAGE‐B score.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularHepatitis B, ChronicLiver NeoplasmsFatty LiverHumansMaleFemaleMiddle AgedRisk FactorsAdultAgedLiver Cirrhosis

Stichwörter der Autor:innen

PAGE‐Bdiabetes mellitus type 2dyslipidemiahypertensionoverweight

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, the Netherlands.
  • Institute of Liver Studies, King's College Hospital, London, UK.
  • Toronto Centre for Liver Disease, Toronto General Hospital, University of Toronto, Toronto, Canada.
  • Liver Unit, Hospital University Valle d'Hebron and CIBEREHD del INstinuto Carlos III, Barcelona, Spain.
  • Department of Gastroenterology and Hepatology, Albert Schweitzer Hospital, Dordrecht, the Netherlands.
  • Department of Internal Medicine and Infectious Diseases, University Medical Center Groningen, Groningen, the Netherlands.

ORCID-Profile: Lesley A Patmore, Willem P Brouwer, Keyur Patel, Maria Buti, Milan J Sonneveld

Förderung

  • Stichting voor Lever- en Maag-Darm Onderzoek
  • Gilead Sciences

Zitieren

APA

Patmore, L. A., Carey, I., Feld, J. J., Brouwer, W. P., Patel, K., Buti, M., Honkoop, P., Postma, D. F., Blokzijl, H., Koc, Ö. M., van Oorschot, E., Agarwal, K., van der Valk, M., Lieveld, F. I., Kilany, M., Kramer, M., de Bruijne, J., Claassen, M. A. A., Hansen, B. E., …, & Sonneveld, M. J. (2026). Prediction of Hepatocellular Carcinoma and Other Liver‐Related Events in Chronic Hepatitis B Patients With Metabolic Dysfunction or Metabolic Dysfunction‐Associated Steatotic Liver Disease. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70360

Vancouver

Patmore LA, Carey I, Feld JJ, Brouwer WP, Patel K, Buti M, et al. Prediction of Hepatocellular Carcinoma and Other Liver‐Related Events in Chronic Hepatitis B Patients With Metabolic Dysfunction or Metabolic Dysfunction‐Associated Steatotic Liver Disease. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70360

BibTeX
@article{Patmore2026,
  author = {Patmore, Lesley A and Carey, Ivana and Feld, Jordan J and Brouwer, Willem P and Patel, Keyur and Buti, Maria and Honkoop, Pieter and Postma, Douwe F and Blokzijl, Hans and Koc, Özgur M and van Oorschot, Eva and Agarwal, Kosh and van der Valk, Marc and Lieveld, Faydra I and Kilany, Mai and Kramer, Matthijs and de Bruijne, Joep and Claassen, Mark A A and Hansen, Bettina E and de Man, Robert A and Janssen, Harry L A and Takkenberg, R Bart and Sonneveld, Milan J},
  title = {Prediction of Hepatocellular Carcinoma and Other Liver‐Related Events in Chronic Hepatitis B Patients With Metabolic Dysfunction or Metabolic Dysfunction‐Associated Steatotic Liver Disease},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1111/apt.70360}
}
Kostenlos starten →